



**R. NAGPAL ASSOCIATES**  
CHARTERED ACCOUNTANTS

B-1/1018, VASANT KUNJ,  
NEW DELHI - 110 070  
TELEPHONE : 011-41082626  
EMAIL : rohit\_mehra@rnaca.in  
rnaca1@gmail.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of **Yatharth Hospital & Trauma Care Services Limited** pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors of  
Yatharth Hospital & Trauma Care Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Yatharth Hospital & Trauma Care Services Limited** (the Company) for the quarter ended June 30, 2024 together with the notes thereon (hereinafter referred to as "the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A



review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the recognition and measurement principles laid down in IND AS 34, prescribed under section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirement of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatements.

5. Other Matter

The Statement includes the results for the quarter ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2024 and the published un-audited year to date figures up to December 31, 2023, which were subjected to a limited review by us, as required under the Listing Regulations.

Our conclusion is not modified in respect of above matter.

For R. Nagpal Associates  
Chartered Accountants  
Firm Registration No. 002626N

  
(CA. Rohit Mehra)

Partner  
Membership No. 093910



UDIN: 24093910 BKAKMO 9418  
Place: Noida  
Date: 13<sup>th</sup> August, 2024

# YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED

Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: [www.yatharthhospitals.com](http://www.yatharthhospitals.com)

Email: [cs@yatharthhospitals.com](mailto:cs@yatharthhospitals.com)



CIN : U85110DL2008PLC174706

## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024

Rs. in Million except Shares and EPS

|             | Particulars                                                                                                                      | Standalone      |                 |                 |                 |
|-------------|----------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
|             |                                                                                                                                  | Quarter Ended   |                 |                 | Year Ended      |
|             |                                                                                                                                  | 30.06.2024      | 31.03.2024      | 30.06.2023      | 31.03.2024      |
|             |                                                                                                                                  | Unaudited       | Audited#        | Unaudited       | Audited         |
| <b>I</b>    | Revenue from operations                                                                                                          | 1,189.64        | 1,055.93        | 1,023.43        | 4,197.91        |
| <b>II</b>   | Other income                                                                                                                     | 26.28           | 50.57           | 3.96            | 135.54          |
| <b>III</b>  | <b>Total Income (I+II)</b>                                                                                                       | <b>1,215.92</b> | <b>1,106.50</b> | <b>1,027.40</b> | <b>4,333.44</b> |
| <b>IV</b>   | <b>Expenses</b>                                                                                                                  |                 |                 |                 |                 |
|             | Medical consumables and pharmacy items consumed                                                                                  | 249.35          | 204.15          | 186.26          | 788.56          |
|             | Employee benefits expense                                                                                                        | 188.01          | 190.35          | 167.68          | 726.02          |
|             | Finance costs                                                                                                                    | 1.08            | 1.86            | 24.23           | 43.05           |
|             | Depreciation and amortisation                                                                                                    | 39.95           | 31.46           | 31.60           | 134.45          |
|             | Other expenses                                                                                                                   | 424.46          | 385.49          | 378.57          | 1,510.22        |
|             | <b>Total expenses (IV)</b>                                                                                                       | <b>902.83</b>   | <b>813.31</b>   | <b>788.34</b>   | <b>3,202.30</b> |
| <b>V</b>    | <b>Profit / (loss) before exceptional items and tax (III-IV)</b>                                                                 | <b>313.09</b>   | <b>293.20</b>   | <b>239.06</b>   | <b>1,131.15</b> |
| <b>VI</b>   | Exceptional items (net)(Gain)/Loss                                                                                               | -               | -               | -               | -               |
| <b>VII</b>  | <b>Profit / (loss) before tax (V-VI)</b>                                                                                         | <b>313.09</b>   | <b>293.20</b>   | <b>239.06</b>   | <b>1,131.15</b> |
| <b>VIII</b> | Tax expense                                                                                                                      |                 |                 |                 |                 |
|             | (1) Current tax                                                                                                                  | 81.69           | 25.52           | 75.53           | 293.29          |
|             | (2) MAT credit entitlement                                                                                                       |                 |                 |                 |                 |
|             | (2) Income tax of earlier years                                                                                                  | -               | -               | -               | -               |
|             | (3) Reversal of MAT credit entitlement of earlier years                                                                          | -               | -               | -               | -               |
|             | (4) Deferred tax                                                                                                                 | (0.07)          | 5.28            | 7.46            | (2.08)          |
|             | <b>Total tax (VIII)</b>                                                                                                          | <b>81.61</b>    | <b>30.80</b>    | <b>82.99</b>    | <b>291.21</b>   |
| <b>IX</b>   | <b>Net Profit/(loss) after tax (VII-VIII)</b>                                                                                    | <b>231.48</b>   | <b>262.39</b>   | <b>156.07</b>   | <b>839.94</b>   |
| <b>X</b>    | <b>Other Comprehensive Income</b>                                                                                                |                 |                 |                 |                 |
|             | A (i) Items that will not be reclassified to profit or loss                                                                      | -               | -               | -               | -               |
|             | (ii) Income tax relating to items that will not be reclassified to profit or loss                                                | -               | -               | -               | -               |
|             | B (i) Items that will be reclassified to profit or loss                                                                          | -               | 1.28            | -               | 1.28            |
|             | (ii) Income tax relating to items that will be reclassified to profit or loss                                                    | -               | (0.32)          | -               | (0.32)          |
|             | <b>Other comprehensive income for the period</b>                                                                                 | -               | <b>0.95</b>     | -               | <b>0.95</b>     |
| <b>XI</b>   | <b>Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)</b> | <b>231.48</b>   | <b>263.35</b>   | <b>156.07</b>   | <b>840.89</b>   |
|             | <b>Profit/(Loss) for the year attributable to:</b>                                                                               |                 |                 |                 |                 |
|             | To the Owners of the company                                                                                                     | <b>231.48</b>   | <b>262.39</b>   | <b>156.07</b>   | <b>839.94</b>   |
|             | Non Controlling Interest                                                                                                         |                 |                 |                 |                 |
|             | <b>Other comprehensive income for the period/year attributable to:</b>                                                           |                 |                 |                 |                 |
|             | To the Owners of the company                                                                                                     | -               | <b>0.95</b>     | -               | <b>0.95</b>     |
|             | Non Controlling Interest                                                                                                         | -               | -               | -               | -               |
|             | <b>Total Comprehensive Income for the period attributable to:</b>                                                                |                 |                 |                 |                 |
|             | To the Owners of the company                                                                                                     | <b>231.48</b>   | <b>263.35</b>   | <b>156.07</b>   | <b>840.89</b>   |
|             | Non Controlling Interest                                                                                                         | -               | -               | -               | -               |
| <b>XII</b>  | Earnings Per Share (Rs.10 each)<br>(Not annualised except for the year ended 31 March 2023)                                      |                 |                 |                 |                 |
|             | Basic                                                                                                                            | 2.70            | 3.32            | 2.38            | 10.61           |
|             | Diluted                                                                                                                          | 2.70            | 3.32            | 2.38            | 10.61           |
|             | Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)                                                          | <b>858.50</b>   | <b>858.50</b>   | <b>655.17</b>   | <b>858.50</b>   |

#refer note no 7 of the accompanying financial results.



**Notes to accounts on the unaudited standalone financial results of Yatharth Hospital & Trauma Care Services Limited for the quarter ended June 30<sup>th</sup>, 2024:**

1. The unaudited standalone financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited for the quarter ended June 30<sup>th</sup>, 2024, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 13<sup>th</sup>, 2024.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
3. The Chief operating decision maker (CODM- CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The group operates in the India and it constitutes the single geographical segment.
4. The Company's revenue from Medical and Healthcare services comprise of income from hospital services and sale of pharmacy items. The Company earns almost all of its revenue from hospital services. The income from sale of food items and rentals are ancillary and thus in terms of IND AS 108, no separate reporting under segment reporting is required.
5. The income tax department conducted searches under section 132 of the Income tax act at the premises belonging to the holding company, subsidiary companies and the key managerial persons of the Company. The Company provided necessary information and data, as required by the Income Tax department and provided the fullest co-operation. The Income tax department took data back-ups and other information. The business operations of the Company continued without any disruptions and the department has so far not raised any income tax demand. The Company shall continue to provide the required co-operation and information to the department and is confident that this search will not cause any additional tax liability on the Company.  
The income tax department has frozen/ created lien on specified amount in the bank accounts and term deposits, valuing Rs 528.60 million. In addition, the Income tax department had also seized Rs 5.21 million out of operational cash.
6. During the previous year FY 2023-24, the Company had completed its Initial Public Offer (IPO) Fresh issue of 16,333,333 Equity Shares aggregating to ₹ 4,900.00 million by our Company ("Fresh Issue") Offer for sale of 6,551,690 Equity Shares aggregating to ₹ 1,965.51 million by the Selling Shareholders ("Offer for Sale"). Further Company has undertaken a Pre-IPO Placement by way of private placement of 4,000,000 Equity Shares for cash at a price of ₹ 300 per Equity Share



aggregating to ₹ 1,200.00 million, in consultation with the BRLMs, pursuant to the resolution of the Board dated July 6, 2023. The size of the Fresh Issue of Equity Shares has been adjusted to ₹ 4,900.00 million. The Company got listed on National Stock Exchange of India and BSE Ltd on 7<sup>th</sup> August 2023.

The utilization of the IPO is summarized below:

(Amount in Million)

| Sr. No | Item Head                                                                                                       | Amount as proposed in the Offer Document | Amount utilized in Rs. Crore   |                    |                           |                          |
|--------|-----------------------------------------------------------------------------------------------------------------|------------------------------------------|--------------------------------|--------------------|---------------------------|--------------------------|
|        |                                                                                                                 |                                          | As at beginning of the quarter | During the quarter | At the end of the quarter | Balance as on 30.06.2024 |
| 1      | Repayment, in full or part, of certain borrowings availed by the company                                        | 100.00                                   | 100.00                         | -                  | 100.00                    | 0.00                     |
| 2      | Repayment, in full or part, of certain borrowings availed by the subsidiaries, AKS and Ramraja                  | 145.00                                   | 142.72                         | -                  | 142.72                    | 2.28                     |
| 3      | Funding capital expenditure, expenses of two hospitals namely Noida and Greater Noida Hospital                  | 25.64                                    | 17.99                          | 7.65               | 25.64                     | 0.00                     |
| 4      | Funding capital expenditure, expenses of subsidiaries; AKS and Ramraja for respective hospital operated by them | 106.97                                   | 30.09                          | 12.30              | 42.40                     | 64.57                    |
| 5      | Funding inorganic growth initiatives through acquisitions and other strategic initiatives                       | 65.00                                    | -                              | 65.00              | 65.00                     | 0.00                     |
| 6      | General Corporate Purposes                                                                                      | 127.10                                   | 41.98                          | 38.01              | 79.99                     | 47.11                    |

7. The figures for the quarter ended 31st March 2024 are the balancing figures between audited figures in respect of full financial year ended 31st March 2024 and published unaudited year to date figures up to 31st December 2023. Previous period/ year figures have been regrouped/ reclassified, wherever necessary, to make them comparable.



8. The aforesaid Statement is available on the Holding Company's website ([www.yatharthhospitals.in](http://www.yatharthhospitals.in)) and on the website of the Stock Exchanges ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)).

On behalf of the Board of Directors  
Yatharth Hospital & Trauma Care Services Ltd.

Dr. Ajay Kumar Tyagi  
Chairman and Whole-time Director



Place: Gr Noida  
Dated: 13/08/2024





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Yatharth Hospital & Trauma Care Services Limited pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors of  
Yatharth Hospital & Trauma Care Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated financial results of **Yatharth Hospital & Trauma Care Services Limited** (the Holding Company) and its subsidiaries (The Holding Company and its Subsidiaries together referred to as 'the Group') for the quarter ended June 30 , 2024 together with the notes thereon (hereinafter referred to as "the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting"("IND AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of



persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulation, to the extent applicable.

4. The Statement includes the results of the following Subsidiaries:
- (i) AKS Medical & Research Centre Private Limited
  - (ii) Ramraja Multispeciality Hospital & Trauma Centre Private Limited
  - (iii) Sanskar Medica India Limited
  - (iv) Pristine Infracon Private Limited

We did not review the financial results of Four subsidiaries included in the consolidated financial results whose financial results reflect Total revenues of Rs. 930.25 Millions, for the quarter ended 30<sup>th</sup> June 2024, total Net Profit after tax of Rs. 51.41 Millions for the quarter ended 30<sup>th</sup> June 2024 and total comprehensive income of Rs. 51.41 Millions for the quarter ended 30<sup>th</sup> June 2024 respectively, as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our Conclusion on above matter is not modified.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the recognition and measurement principles laid down in IND AS 34, prescribed under section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirement of Regulation 33 of the




Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatements.

6. Other Matter

The Statement includes the results for the quarter ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2024 and the published un-audited year to date figures up to December 31, 2023, which were subjected to a limited review by us, as required under the Listing Regulations.

Our conclusion is not modified in respect of above matter

For R. Nagpal Associates  
Chartered Accountants  
Firm Registration No. 002626N



(CA. Rohit Mehra)  
Partner  
Membership No. 093910

UDIN: 24093910BKAKNP2513

Place: Noida

Date: 13<sup>th</sup> August 2024

# YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED

Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: [www.yatharthhospitals.com](http://www.yatharthhospitals.com)

Email: [cs@yatharthhospitals.com](mailto:cs@yatharthhospitals.com)

CIN : U85110DL2008PLC174706

## STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024

Rs. in Million except Shares and EPS

|             | Particulars                                                                                                                      | Consolidated    |                 |                 |                 |
|-------------|----------------------------------------------------------------------------------------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
|             |                                                                                                                                  | Quarter Ended   |                 |                 | Year Ended      |
|             |                                                                                                                                  | 30.06.2024      | 31.03.2024      | 30.06.2023      | 31.03.2024      |
|             |                                                                                                                                  | Unaudited       | Audited#        | Unaudited       | Audited         |
| <b>I</b>    | Revenue from operations                                                                                                          | 2,117.83        | 1,777.53        | 1,545.07        | 6,705.47        |
| <b>II</b>   | Other income                                                                                                                     | 36.53           | 56.56           | 7.57            | 156.10          |
| <b>III</b>  | <b>Total Income (I+II)</b>                                                                                                       | <b>2,154.36</b> | <b>1,834.09</b> | <b>1,552.63</b> | <b>6,861.58</b> |
| <b>IV</b>   | <b>Expenses</b>                                                                                                                  |                 |                 |                 |                 |
|             | Medical consumables and pharmacy items consumed                                                                                  | 468.04          | 374.75          | 280.52          | 1,333.11        |
|             | Employee benefits expense                                                                                                        | 346.07          | 318.67          | 268.38          | 1,170.23        |
|             | Finance costs                                                                                                                    | 29.17           | 3.80            | 59.29           | 94.18           |
|             | Depreciation and amortisation                                                                                                    | 114.43          | 76.96           | 68.74           | 293.00          |
|             | Other expenses                                                                                                                   | 767.07          | 618.79          | 582.03          | 2,402.74        |
|             | <b>Total expenses (IV)</b>                                                                                                       | <b>1,724.78</b> | <b>1,392.97</b> | <b>1,258.95</b> | <b>5,293.26</b> |
| <b>V</b>    | <b>Profit / (loss) before exceptional items and tax (III-IV)</b>                                                                 | <b>429.58</b>   | <b>441.12</b>   | <b>293.68</b>   | <b>1,568.32</b> |
| <b>VI</b>   | Exceptional items (net)(Gain)/Loss                                                                                               | -               | -               | -               | -               |
| <b>VII</b>  | <b>Profit / (loss) before tax (V-VI)</b>                                                                                         | <b>429.58</b>   | <b>441.12</b>   | <b>293.68</b>   | <b>1,568.32</b> |
| <b>VIII</b> | Tax expense                                                                                                                      |                 |                 |                 |                 |
|             | (1) Current tax                                                                                                                  | 136.10          | 42.90           | 102.59          | 402.78          |
|             | (2) MAT credit entitlement                                                                                                       |                 |                 |                 |                 |
|             | (2) Income tax of earlier years                                                                                                  | -               | 0.01            | -               | 0.01            |
|             | (3) Reversal of MAT credit entitlement of earlier years                                                                          | -               | -               | -               | 4.88            |
|             | (4) Deferred tax                                                                                                                 | (10.35)         | 14.71           | 0.73            | 15.91           |
|             | <b>Total tax (VIII)</b>                                                                                                          | <b>125.74</b>   | <b>57.62</b>    | <b>103.32</b>   | <b>423.57</b>   |
| <b>IX</b>   | <b>Net Profit/(loss) after tax (VII-VIII)</b>                                                                                    | <b>303.84</b>   | <b>383.49</b>   | <b>190.36</b>   | <b>1,144.75</b> |
| <b>X</b>    | <b>Other Comprehensive Income</b>                                                                                                |                 |                 |                 |                 |
|             | A (i) Items that will not be reclassified to profit or loss                                                                      | -               | -               | -               | -               |
|             | (ii) Income tax relating to items that will not be reclassified to profit or loss                                                | -               | -               | -               | -               |
|             | B (i) Items that will be reclassified to profit or loss                                                                          | -               | 1.52            | -               | 1.52            |
|             | (ii) Income tax relating to items that will be reclassified to profit or loss                                                    | -               | (0.39)          | -               | (0.39)          |
|             | <b>Other comprehensive income for the period</b>                                                                                 | -               | <b>1.13</b>     | -               | <b>1.13</b>     |
| <b>XI</b>   | <b>Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)</b> | <b>303.84</b>   | <b>384.62</b>   | <b>190.36</b>   | <b>1,145.87</b> |
|             | <b>Profit/(Loss) for the year attributable to:</b>                                                                               |                 |                 |                 |                 |
|             | To the Owners of the company                                                                                                     | 303.84          | 383.49          | 190.36          | 1,144.75        |
|             | Non Controlling Interest                                                                                                         |                 |                 |                 |                 |
|             | <b>Other comprehensive income for the period/year attributable to:</b>                                                           |                 |                 |                 |                 |
|             | To the Owners of the company                                                                                                     | -               | 1.13            | -               | 1.13            |
|             | Non Controlling Interest                                                                                                         | -               | -               | -               | -               |
|             | <b>Total Comprehensive Income for the period attributable to:</b>                                                                |                 |                 |                 |                 |
|             | To the Owners of the company                                                                                                     | 303.84          | 384.62          | 190.36          | 1,145.87        |
|             | Non Controlling Interest                                                                                                         | -               | -               | -               | -               |
| <b>XII</b>  | Earnings Per Share (Rs.10 each)<br>(Not annualised except for the year ended 31 March 2023)                                      |                 |                 |                 |                 |
|             | Basic                                                                                                                            | 3.54            | 4.85            | 3.04            | 14.46           |
|             | Diluted                                                                                                                          | 3.54            | 4.85            | 3.04            | 14.46           |
|             | Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)                                                          | 858.50          | 858.50          | 655.17          | 858.50          |

#refer note no 8 of the accompanying financial results.



**Notes to accounts on the unaudited consolidated financial results of Yatharth Hospital & Trauma Care Services Limited for the quarter ended June 30<sup>th</sup>, 2024:**

1. The unaudited consolidated financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited ('the Holding Company') along with its subsidiaries for the quarter ended June 30<sup>th</sup>, 2024, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 13<sup>th</sup> 2024.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
3. The Chief operating decision maker (CODM- CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The group operates in the India and it constitutes the single geographical segment.
4. The Company's revenue from Medical and Healthcare services comprise of income from hospital services and sale of pharmacy items. The Company earns almost all of its revenue from hospital services. The income from sale of food items and rentals are ancillary and thus in terms of IND AS 108, no separate reporting under segment reporting is required.
5. The income tax department conducted searches under section 132 of the Income tax act at the premises belonging to the holding company, subsidiary companies and the key managerial persons of the Company. The Company provided necessary information and data, as required by the Income Tax department and provided the fullest co-operation. The Income tax department took data back-ups and other information. The business operations of the Company continued without any disruptions and the department has so far not raised any income tax demand. The Company shall continue to provide the required co-operation and information to the department and is confident that this search will not cause any additional tax liability on the Company.  
The income tax department has frozen/ created lien on specified amount in the bank accounts and term deposits, valuing Rs 706.25 million. In addition the Income tax department had also seized Rs 8.6 million out of operational cash.
6. During the previous year FY 2023-24, the Company had completed its Initial Public Offer (IPO) Fresh issue of 16,333,333 Equity Shares aggregating to ₹ 4,900.00 million by our Company ("Fresh Issue") Offer for sale of 6,551,690 Equity Shares aggregating to ₹ 1,965.51 million by the Selling Shareholders ("Offer for Sale"). Further Company has undertaken a Pre-IPO Placement by way of private placement of 4,000,000 Equity Shares for cash at a price of ₹ 300 per Equity Share aggregating to ₹ 1,200.00 million, in consultation with the BRLMs, pursuant to the resolution of



the Board dated July 6, 2023. The size of the Fresh Issue of Equity Shares has been adjusted to ₹ 4,900.00 million. The Company got listed on National Stock Exchange of India and BSE Ltd on 7<sup>th</sup> August 2023.

The utilization of the IPO is summarized below:

(Amount in Million)

| Sr. No | Item Head                                                                                                       | Amount as proposed in the Offer Document | Amount utilized in Rs. Crore   |                    |                           |                          |
|--------|-----------------------------------------------------------------------------------------------------------------|------------------------------------------|--------------------------------|--------------------|---------------------------|--------------------------|
|        |                                                                                                                 |                                          | As at beginning of the quarter | During the quarter | At the end of the quarter | Balance as on 30.06.2024 |
| 1      | Repayment, in full or part, of certain borrowings availed by the company                                        | 100.00                                   | 100.00                         | -                  | 100.00                    | 0.00                     |
| 2      | Repayment, in full or part, of certain borrowings availed by the subsidiaries, AKS and Ramraja                  | 145.00                                   | 142.72                         | -                  | 142.72                    | 2.28                     |
| 3      | Funding capital expenditure, expenses of two hospitals namely Noida and Greater Noida Hospital                  | 25.64                                    | 17.99                          | 7.65               | 25.64                     | 0.00                     |
| 4      | Funding capital expenditure, expenses of subsidiaries; AKS and Ramraja for respective hospital operated by them | 106.97                                   | 30.09                          | 12.30              | 42.40                     | 64.57                    |
| 5      | Funding inorganic growth initiatives through acquisitions and other strategic initiatives                       | 65.00                                    | -                              | 65.00              | 65.00                     | 0.00                     |
| 6      | General Corporate Purposes                                                                                      | 127.10                                   | 41.98                          | 38.01              | 79.99                     | 47.11                    |

7. In respect of subsidiary company i.e Pristine Infratech Pvt Limited
- The operations of the hospital were resumed w.e.f. 12<sup>th</sup> May 2024. There has been non compliance towards filing of return of income for the FY ended 2023 by the erstwhile promoters.
  - Few ex-employees had initiated the legal proceedings against the Company at Labour Court for the recovery of their pending dues before the acquisition of the company. Now the Company is in the process of settling with the ex-employees. As per the agreement any liability will be borne by the erstwhile promoters/ selling shareholders.



8. The figures for the quarter ended 31st March 2024 are the balancing figures between audited figures in respect of full financial year ended 31st March 2024 and published unaudited year to date figures up to 31st December 2023. Previous period/ year figures have been regrouped/ reclassified, wherever necessary, to make them comparable.
9. The aforesaid Statement is available on the Holding Company's website ([www.yatharthhospitals.in](http://www.yatharthhospitals.in)) and on the website of the Stock Exchanges ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) ).

On behalf of the Board of Directors  
Yatharth Hospital & Trauma Care Services Ltd.

  
Dr. Ajay Kumar Tyagi  
Chairman and Whole-time Director



Place: Gr Noida  
Dated: 13/08/2024

